Pharmaceutically active sulfonyl amino acid derivatives

Details Pharmaceutically active sulfonyl amino acid derivatives Pharmaceutically active sulfonyl amino acid derivatives

2000-09-28

2009-12-29

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S280400

Reexamination Certificate

active

07638538

ABSTRACT:
The present invention is related to sulfonyl amino acid derivatives of formula (I), notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonyl amino acid derivatives. Said sulfonyl amino acid are efficient modulators of the JNK pathway, they are in particular efficient inhibitors of JNK 2 and 33. The present invention is furthermore related to novel sulfonyl amino acid derivatives as well as to methods of their preparation.

REFERENCES:
patent: 3396030 (1968-08-01), Haas et al.
patent: 6172261 (2001-01-01), Vermeulin et al.
patent: 6503901 (2003-01-01), Thompson et al.
patent: 6646149 (2003-11-01), Vermeulin et al.
patent: 0 757 984 (1997-02-01), None
patent: 1085011 (2001-03-01), None
patent: 2 312 242 (1976-12-01), None
patent: 11 236369 (1999-09-01), None
patent: 11 246527 (1999-09-01), None
patent: 98 03166 (1998-01-01), None
patent: 98 39329 (1998-09-01), None
patent: 98 49188 (1998-11-01), None
patent: 99 42443 (1999-08-01), None
Okamoto et al. “Lysine derivative and proteinase inhibitor” CA 105:97950 (1986).
CAS RN 150-13-0.
Bozyczko-Coyne et al. “Targeting the JNK pathway . . . ” PMID;12769633 (2002).
Wilbraham et al. “Organic and biological chemistry” S, Ill. Univ. p. 222-225 (1985).
Arkinstall “preparation o N-arylsulfonyl amino acid . . . ” CA 134:266198 (2001).
Autoimmune diseases Medical dictionary online (1997).
Baker Botts “Reach through claims” (2002).
Trilateral project B3b “comparative stuy on reach through claims” (2001).
Exhibit I.
Kumagae et al. “Human c-Jun . . . ” Mole. Brain Res. v.67, p. 10-17 (1999).
Shau et al. “The crystal . . . ” J. Mo. Biol. v.383, p. 885-893 (2008).
Scapin et al. “The structure of JNK3 . . . ” Chem. & Biol. v.10, p. 705-712 (2003).
Ragab A. El-Sayed: “A facile synthesis and some new reactions of N-benzylcarboxamides with essential amino acids” Indian J. Chem., 37B(10), pp. 1059-1062 1998.
Ragab A. El-Sayed: “A comparative study of the reactions of thiophene-2-carboxanilides and related compounds” J. Serb. Chem. Soc., 63(5), pp. 371-377 1998.
M.H. El-Hakim: “Synthesis and antimicrobial activity of some new 2- and 4-chlorobenzanilide p-sulfonylamino acid and dipeptide derivatives”.
Ragab A. El-Sayed: “Some novel sulfanilyl amino acid derivatives” J. Serb. Chem. Soc., 56(6), pp. 311-318 1991.
Xiaoling Xie et al.: “Crystal structure of JNK3: a kinase implicated in neuronal apoptosis” Structure, 6 (8), pp. 983-991 1998.
Derek D. Yang et al.: “Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene” Nature, 389 (6653), pp. 865-870 1997.
Derek D. Yang et al.: “Differentiation of DC4+ T Cells to Th- cells requires MAP kinase JNK2” Immunity, 9, pp. 575-585 1998.
Kanaga Sabapathy et al.: “JKN2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development” Current Biology, 9, pp. 116-125 1999.
Yoshihiro Kumagae et al.: “Human c-Jun N-terminal kinase expression and activation in the nervous system” Brain Res. Mol. Brain Res., 67(1), pp. 10-17 1999.
U.S. Appl. No. 10/088,074, filed Mar. 20, 2002, Arkinstall, et al.
U.S. Appl. No. 10/070,954, filed Mar. 13, 2002.
U.S. Appl. No. 12/142,296, filed Jun. 19, 2008, Halazy, et al.

Affiliated with

Also associated with

Rating

Pharmaceutically active sulfonyl amino acid derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutically active sulfonyl amino acid derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutically active sulfonyl amino acid derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4134524